多吉美聯合介入治疗原发性肝癌的疗效分析.doc
文本预览下载声明
多吉美联合介入治疗原发性肝癌的疗效分析
(附20例病例报告)
作者:李枫,王峰,李军,杨新顺
单位:大连医科大学附属第一医院介入治疗科 辽宁大连 116001
第一作者:李枫,男,1973-05-16生,辽宁大连人,汉族,2003年获中国医科大学影像医学与核医学专业硕士学位,主治医师,主要从事肿瘤的介入治疗
E-mail:lifeng120@263.net
T
通讯作者:王峰 大连医科大学附属第一医院介入治疗科 辽宁大连 116001
多吉美联合介入治疗原发性肝癌的疗效分析
(附20例病例报告)
李枫,王峰,李军,杨新顺
Efficacy analysis of Nexavar combined interventional therapy for hepatocellular carcinoma (study of 20 cases)
Feng Li, Feng Wang, Jun Li, Xin-Shun Yang
Feng Li, Feng Wang, Jun Li, Xin-Shun Yang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China
Correspondence to: Feng Wang, Department of Interventional therapy, The First Affiliated Hospital of Dalian Medical University, Dalian 116001, China.
Abstract
AIM: To study the efficacy comparison between Nexavar monotherapy and combined interventional therapy for treatment of hepatocellular carcinoma.
METHODS: Retrospective analysis of 20 cases who systemly taking Nexavar for hepatocellular carcinoma, including 7 cases of Nexavar monotherapy, 13 cases combined interventional therapy. All patients was followed up by hospital or out-patient for 7-28 months. Primary study endpoint was tumor response rate and time to tumor progression(TTP).
RESULTS: In 20 cases, 4 were achieved complete response (CR), 10 were partial response (PR), 4 with stable disease (SD) and 2 with progressed disease (PD). In Nexavar monotherapy group, CR was 0, PR was 3, SD was 2 and PD was 2. The median time to tumor progression was 16 weeks and 48 weeks respectively for Monotherapy group and combined treatment group.
CONCLUSION: Nexavar combined interventional therapy for hepatocellular carcinoma can increase the tumor response rate, extend the time to tumor progression.
Key words: Nexavar;interventional therapy;hepatocellular carcinoma;efficacy
摘要
目的:研究多吉美单药治疗肝癌与联合介入治疗的疗效对比。
方法:回顾性分析20例系统服用多吉美的肝癌患者,其中单药治疗的7例,联合介入治疗的13例,随访方式采用门诊随访及住院随访,随访时间7-28月。主要研究终点为肿瘤反应率和肿瘤进展时间。
结果:20例患者中,CR 4例,PR 1
显示全部